Advances in Targeted Protein Degradation
Discover Glo Webinar Series
Series Summary:
Over the last 30 years, assays and technologies utilizing the natural phenomenon of bioluminescence have gone from novel research tools to foundational elements of the modern research toolbox. Innovation utilizing bioluminescent approaches continues, further expanding both the available methods and the scientific advancements made by life science and drug discovery researchers. In this webinar series you will hear from industry experts and Promega scientists who will share research updates on important research topics included Kinases, GPCRs, and Targeted Protein Degradation. You will also learn about recent technology advancements that can be applied to these as well as other drug targets and research areas.
Session 4 - Advances in Targeted Protein Degradation
Summary
Selectively targeting proteins for degradation and removal from the cell is an exciting new therapeutic approach that is expanding our definition of the druggable proteome. This approach involves developing novel small molecules that can modulate protein-protein interactions inside the cell, sending the target protein through the cell’s natural ubiquitin proteasome pathway. In this session two leading experts in the field of targeted protein degradation will present new insights into cellular processes that can be utilized for targeting proteins for degradation and methods and techniques for the assessment of target protein dynamics.
Other webinars in this series:
Bioluminescence: Past, Present, Future
Applications of CRISPR Knock-in Tagging for Studying Endogenous Protein Dynamics
Speakers
Dr. Alessio Ciulli
Professor of Chemical and Structural Biology
University of Dundee, School of Life Sciences
Alessio Ciulli is a Professor of Chemical Structural Biology at the School of Life Sciences, University of Dundee, and the Director of Dundee’s new Centre for Targeted Protein Degradation (CeTPD). He obtained his M.Sc. (University of Florence) and Ph.D. degrees (University of Cambridge) in Chemistry, followed by post-doctoral research at Cambridge and a visiting fellowship at Yale University. The Ciulli Lab focuses on the design and application of small molecules targeting protein interactions and protein degradation. He has made fundamental contributions to the development of the PROTAC field, and is the scientific founder of Amphista therapeutics, a company that develops novel medicines through targeted protein degradation. He has won numerous prizes and awards and is a Fellow of the Royal Society of Chemistry.
Dr. Danette Daniels
Senior Research Scientist and Group Leader, Functional Proteomics
Promega Corporation
Danette received her B.A. from Columbia University, a Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying the Wnt signaling pathway. In 2005 she joined Promega Corporation and is currently a R&D Group Leader of Functional Proteomics. In her time at Promega she has led innovation and applications of HaloTag, chemoproteomics, NanoBRET, and HiBiT luciferase technologies. Danette is known for her extensive research collaborations, both with academic laboratories as well as biotech and pharma companies. These partnerships have resulted in discoveries of several novel epigenetic and transcription complexes, as well as characterization of numerous therapeutic inhibitors. Several years ago she and her team shifted focus to TPD, immediately developing approaches to monitor real-time kinetics of degradation and PROTAC induced interactions. These efforts have advanced understanding of cellular potency, efficacy, and mechanisms of degradation compounds.